Trexquant Investment LP Makes New Investment in REGENXBIO Inc. (NASDAQ:RGNX)

Trexquant Investment LP acquired a new stake in REGENXBIO Inc. (NASDAQ:RGNX - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 150,022 shares of the biotechnology company's stock, valued at approximately $1,160,000. Trexquant Investment LP owned about 0.30% of REGENXBIO as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. JPMorgan Chase & Co. grew its holdings in shares of REGENXBIO by 67.0% in the fourth quarter. JPMorgan Chase & Co. now owns 4,136,517 shares of the biotechnology company's stock worth $31,975,000 after purchasing an additional 1,659,206 shares during the last quarter. Geode Capital Management LLC boosted its position in REGENXBIO by 0.5% in the 4th quarter. Geode Capital Management LLC now owns 1,094,225 shares of the biotechnology company's stock valued at $8,460,000 after buying an additional 5,574 shares during the period. Assenagon Asset Management S.A. grew its stake in REGENXBIO by 53.0% in the 4th quarter. Assenagon Asset Management S.A. now owns 856,572 shares of the biotechnology company's stock worth $6,621,000 after acquiring an additional 296,700 shares in the last quarter. Norges Bank purchased a new position in shares of REGENXBIO during the fourth quarter worth approximately $3,474,000. Finally, Charles Schwab Investment Management Inc. raised its stake in shares of REGENXBIO by 9.7% during the third quarter. Charles Schwab Investment Management Inc. now owns 417,739 shares of the biotechnology company's stock valued at $4,382,000 after acquiring an additional 37,055 shares in the last quarter. Hedge funds and other institutional investors own 88.08% of the company's stock.

Remove Ads

REGENXBIO Stock Performance

RGNX traded up $0.30 on Tuesday, hitting $6.63. The company had a trading volume of 589,582 shares, compared to its average volume of 794,830. The stock has a market capitalization of $332.28 million, a price-to-earnings ratio of -1.32 and a beta of 1.26. The stock has a fifty day moving average price of $6.95 and a 200-day moving average price of $8.24. REGENXBIO Inc. has a 12-month low of $5.04 and a 12-month high of $18.65.

REGENXBIO (NASDAQ:RGNX - Get Free Report) last issued its quarterly earnings data on Thursday, March 13th. The biotechnology company reported ($1.01) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.27) by $0.26. REGENXBIO had a negative net margin of 283.19% and a negative return on equity of 70.65%. The firm had revenue of $21.21 million for the quarter, compared to the consensus estimate of $23.70 million. Analysts forecast that REGENXBIO Inc. will post -4.84 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on RGNX shares. StockNews.com raised REGENXBIO from a "sell" rating to a "hold" rating in a research note on Friday, March 7th. HC Wainwright dropped their price target on REGENXBIO from $36.00 to $34.00 and set a "buy" rating on the stock in a research report on Monday, March 17th. Morgan Stanley raised their price target on REGENXBIO from $22.00 to $24.00 and gave the company an "overweight" rating in a research note on Friday, March 14th. The Goldman Sachs Group lowered shares of REGENXBIO from a "buy" rating to a "neutral" rating and lowered their price objective for the stock from $38.00 to $14.00 in a research note on Tuesday, February 11th. Finally, Royal Bank of Canada reissued an "outperform" rating and set a $30.00 target price on shares of REGENXBIO in a research report on Tuesday, January 21st. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $31.88.

REGENXBIO Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.